Klotho Neurosciences, Inc.(KLTOW)Earnings, Financials & Key Ratios
KLTOW•NASDAQ
$0.09
Price updated Jun 20, 2026
AboutKlotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.Show more
- Revenue$0
- EBITDA-$6M-817.8%
- Net Income-$6M-769.4%
- EPS (Diluted)-0.32-769.6%
- ROE-700.07%-766.3%
KLTOW Price & Volume
Klotho Neurosciences, Inc. (KLTOW) stock price & volume — 10-year historical chart
Loading chart...
Pre-Revenue Biotech Faces Severe Liquidity Constraints
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
"Klotho Neurosciences remains in a high-risk, pre-revenue stage, relying entirely on external capital to fund its preclinical gene therapy research. The company's financial profile is characterized by escalating administrative overhead, which reached $1.6 million in 2025Q3, and a reliance on equity-based compensation to preserve cash. Investors should monitor the sustainability of its $9.9 million equity base against the backdrop of cumulative retained earnings losses totaling $19.8 million."
Verdict Logic
the company's precarious financial position is highlighted by a $1.9 million operating loss in 2025Q3 and a history of erratic cash burn that threatens long-term operational continuity.
KLTOW Growth Metrics
Klotho Neurosciences, Inc. (KLTOW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-168.2%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM8.11%
Return on Capital
10 Years-213.55%
5 Years-213.55%
3 Years-248.72%
Last Year-621.96%
Peers Comparison
Key metrics vs top competitors for Klotho Neurosciences, Inc. (KLTOW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.09 | $1.66M | -0.27 | — | — | -700.07% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — | |
| $3.73 | $64.48M | -2.78 | — | -1070.26% | — | — | |
| $1.72 | $33.84M | -1.23 | — | — | -318.08% | — | |
| $2.56 | $260.54M | -2.96 | -86.92% | -1971.7% | -101.76% | — | |
| $216.03 | $31.89B | 24.47 | 1.39% | 13.92% | 7.55% | — |
Compare KLTOW vs Peers
Klotho Neurosciences, Inc. (KLTOW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when KLTOW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KLTOW Frequently Asked Questions
Klotho Neurosciences, Inc. (KLTOW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is KLTOW profitable?
Klotho Neurosciences, Inc. (KLTOW) reported a net loss of $11.3M for fiscal year 2024.
Dividend & Returns
What is KLTOW's return on equity?
Klotho Neurosciences, Inc. (KLTOW) has a return on equity (ROE) of -700.1%. Negative ROE indicates the company is unprofitable.
What is Klotho Neurosciences, Inc.'s free cash flow?
Klotho Neurosciences, Inc. (KLTOW) had negative free cash flow of $5.6M in fiscal year 2024, likely due to heavy capital investments.